Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2012

View Archived Issues

Promising data presented from phase II Cinryze combination trial

GeoVax obtains FDA approval to advance adjuvanted HIV vaccine to clinic

Studies address suitability of allopregnanolone to treat Niemann-Pick disease type C

GM-CSF-adjuvanted vaccine provides long-term protection in HIV model

Hadasit Bio-Holdings to receive further funding from Israeli government

FDA approves first cell-based product made from allogeneic human cells and bovine collagen

Immunogenicity and favorable tolerability reported for H5N1 flu vaccine

New data reported on biOasis immunoconjugate for HER2+ breast cancer

Epistem and GlaxoSmithKline enter biomarker collaboration

Enrollment begins in phase I RX-3117 trial

Calcium channel blocker for hypertension clear to enter clinical testing in China

PX'Therapeutics begins phase I trial of HIV vaccine

Calzada subsidiary discloses encouraging in vitro data on AOD-9603

Hybrigenics clear to conduct phase II inecalcitol study in CLL

Hutchison MediPharma reports new JAK inhibitors

Merck KGaA announces new inhibitors of FADK 1

Isotechnika and FDA reach SPA agreement on voclosporin trial

Novel caspase inhibitors discovered at Banyan Biomarkers

Phase I study of CBLB-502 advances

Novel apoptosis inducers prepared by U.S. university scientists

New Trevena G protein-biased mu opioid receptor ligand has analgesic activity

New RSV vaccines developed at GenVec

Phase III OMS-302 study meets endpoints

FDA accepts CRTX-080 NDA for filing

Attogen patents novel FGFR2IIIc-specific antibodies

Abbott identifies new potential analgesics

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...